VC and Investment
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Today's issue
Refine Search
Pharmaceutical
The announcement that 700 US jobs are to be cut by one of pharma’s big names comes in the week that two other leading companies are to slash their workforce. 9 December 2016
Generics
Mylan cut could up to 10% of its workforce. 8 December 2016
Biotechnology
UK biotech Kymab has taken a major step forward in advancing its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies. 24 November 2016
Biotechnology
An update on the progress of its pipeline has shown the strength of an Israeli drugmaker – and this time it is not Teva. 24 November 2016
Pharmaceutical
Spanish drugmaker Grifols raised 1 billion euros ($1.06 billion) in revenue in the third quarter of 2016, a 3% increase compared with the same period the previous year. 18 November 2016
Generics
The share price of Israeli generics giant Teva dropped by more than 8% on Tuesday, when the company announced its third quarter results. 16 November 2016
Biotechnology
Ireland-incorporated Shire closed 3.7% higher at £5,087 on Thursday after it showcased a strong rare diseases pipeline and commercial portfolio in an investor day. 10 November 2016
Generics
Jordan-based Hikma Pharmaceuticals (was trading 4% lower as Thursday’s trading neared its end while markets digested its third-quarter trading update. 10 November 2016
Generics
Netherlands-based drugmaker Mylan has reported a $119.8 million loss for the third quarter of 2016. 10 November 2016
Biotechnology
The struggles and successes of UK biotechs in raising capital show the particular challenges of accessing funds on different sides of the Atlantic, as Chris Pettigrew of Novasecta explores in our expert view piece. 8 November 2016
Pharmaceutical
Spain’s leading drugmaker Almirall has reported revenues for 2016’s first three quarters which are 6.7% higher than in the same period last year. 7 November 2016
Pharmaceutical
Ireland-incorporated Allergan might have seen its third quarter revenue rise by 4.4% compared to the same period last year, but the $3.62 billion total was shy of analyst estimates of $3.68 billion. 3 November 2016
Pharmaceutical
Shares in cancer drug developer Verastem and pharma company Infinity Pharmaceuticals both dropped significantly on Wednesday after the US companies announced a $28 million licensing deal on an oncology candidate. 3 November 2016
Pharmaceutical
Shire has billed its third-quarter results as record-breaking, but markets are less convinced as the Ireland-incorporated company’s share price has dropped by 2.1% since they were presented on Tuesday. 1 November 2016
Pharmaceutical
Third Rock Ventures is to spend proceeds from its latest $616 million fundraising drive on investing in healthcare firms with a particular emphasis on innovative product engine companies in areas including oncology, immunology, neurological disorders, cardiovascular disease and rare genetic diseases. 1 November 2016
Pharmaceutical
The share price of US drugmaker AbbVie was in decline again on Monday morning after revenue levels in its third quarter results fell below analysts’ predictions. 31 October 2016
Pharmaceutical
US healthcare giant Johnson & Johnson reported sales of $17.8 billion for the third quarter of 2016, a 4.2% increase compared to the same period last year. 18 October 2016
Pharmaceutical
Swiss pharma giant Novartis is to close two research units and cut around 175 jobs as part of a new research strategy. 6 October 2016
Pharmaceutical
Around 1,000 jobs are to go at Danish diabetes giant Novo Nordisk, which amounts to nearly 2.4% of its total global workforce.
This action has been described in a statement as “one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market.” 29 September 2016
Pharmaceutical
Pfizer has ended speculation that it is to split by announcing that it will remain one company. 26 September 2016
Biotechnology
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Biotechnology
Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with participation from new investors Sanofi and Invus 25 October 2024
Pharmaceutical
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
Biotechnology
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024
Biotechnology
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
Pharmaceutical
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
Pharmaceutical
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
Pharmaceutical
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Biotechnology
In Cambridge, UK, the protein specialist Nuclera has raised $75 million in a funding round led by Elevage Medical Technologies and backed by Patient Square Capital. 16 October 2024
Biotechnology
Tolerance Bio has announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners. 16 October 2024
Biotechnology
In Hong Kong, Akeso Biopharma has successfully raised $250 million through a share placement, marking its second major fundraising effort of 2024. 15 October 2024
Pharmaceutical
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Biotechnology
Boston, USA-based Upstream Bio, a biotech developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, has made an impressive start to life as a public-listed company.00000 14 October 2024
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze